Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00500058
Status:
COMPLETED
Last Update Posted:
2017-07-26
First Post:
2007-07-10
Brief Title:
A Phase I Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase I Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 SB-485232 Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-HodgkinsLymphoma
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose is to identify a dose of SB-485232 which is safe tolerable and effective when used in combination with Rituximab in patients with non-Hodgkins lymphoma NHL This study will use a standard treatment regimen of Rituximab in combination with rising doses of SB-485232 The dose selected from this study will be used in a future studies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None